Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations

European Journal of Cancer

Volumn 48, Issue 12, 2012, Pages 1842-1852

  Schoenewolf, Nicola L ^a   Bull, Christian ^a   Belloni, Benedetta ^a   Holzmann, David ^b   Tonolla, Sabina ^a   Lang, Roland ^c   Mihic Probst, Daniela ^b   Andres, Christian ^d   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acrolentiginous melanoma; KIT; KIT expression; KIT targeted therapy; Mucosal melanoma

Indexed keywords

IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; SORAFENIB;

ACROLENTIGINOUS MELANOMA; ADULT; AGED; ANAL MELANOMA; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOOT MELANOMA; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIT GENE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; METASTASIS; MUCOSA; MUCOSAL MELANOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VULVOVAGINAL MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NOSE NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS; VULVAR NEOPLASMS;

EID: 84864121795     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.02.049     Document Type: Article

References (43)

1. J.A. Curtin, J. Fridlyand, and T. Kageshita Distinct sets of genetic alterations in melanoma The New England journal of medicine 353 20 2005 2135 2147
2. H. Davies, G.R. Bignell, and C. Cox Mutations of the BRAF gene in human cancer Nature 417 6892 2002 949 954
3. C. Cohen, A. Zavala-Pompa, and J.H. Sequeira Mitogen-actived protein kinase activation is an early event in melanoma progression Clin Cancer Res. 8 12 2002 3728 3733
4. V. Gray-Schopfer, C. Wellbrock, and R. Marais Melanoma biology and new targeted therapy Nature. 445 7130 2007 851 857
5. R.D. Carvajal, C.R. Antonescu, and J.D. Wolchok KIT as a Therapeutic Target in Metastatic Melanoma JAMA 305 22 2011 2327 2334
6. C.R. Antonescu, K.J. Busam, and T.D. Francone L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition Int J Cancer. 121 2 2007 257 264
7. A. Ashida, M. Takata, and H. Murata Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas Int J Cancer. 124 4 2009 862 868
8. C. Beadling, E. Jacobson-Dunlop, and F.S. Hodi KIT gene mutations and copy number in melanoma subtypes Clin Cancer Res. 14 21 2008 6821 6828
9. J.A. Curtin, K. Busam, D. Pinkel, and B.C. Bastian Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol. 24 26 2006 4340 4346
10. F.S. Hodi, P. Friedlander, C.L. Corless, and M.C. Heinrich Mac Rae S, Kruse A, et al. Major response to imatinib mesylate in KIT-mutated melanoma J Clin Oncol. 26 12 2008 2046 2051
11. J.A. Holden, C. Willmore-Payne, and L.J. Layfield Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology Experimental and molecular pathology. 85 1 2008 68 75
12. X. Jiang, J. Zhou, and N.K. Yuen Imatinib targeting of KIT-mutant oncoprotein in melanoma Clin Cancer Res. 14 23 2008 7726 7732
13. J. Lutzky, J. Bauer, and B.C. Bastian Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation Pigment cell & melanoma research. 21 4 2008 492 493
14. S.R. McLean, M. Gana-Weisz, and B. Hartzoulakis Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala Mol Cancer Ther. 4 12 2005 2008 2015
15. A. Quintas-Cardama, A.J. Lazar, and S.E. Woodman Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib Nat Clin Pract Oncol. 5 12 2008 737 740
16. R.S. Rivera, H. Nagatsuka, and M. Gunduz C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma Virchows Archiv: an international journal of pathology. 452 1 2008 27 32
17. I. Satzger, U. Kuttler, and B. Volker Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy-case report and review of the literature Dermatology. 220 1 2010 77 81
18. I. Satzger, T. Schaefer, and U. Kuettler Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas Br J Cancer. 99 12 2008 2065 2069
19. P. Terheyden, R. Houben, and P. Pajouh Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene J Invest Dermatol. 130 1 2010 314 316
20. C. Willmore-Payne, J.A. Holden, S. Hirschowitz, and L.J. Layfield BRAF and c-kit gene copy number in mutation-positive malignant melanoma Human pathology. 37 5 2006 520 527
21. C. Willmore-Payne, J.A. Holden, S. Tripp, and L.J. Layfield Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis Human pathology. 36 5 2005 486 493
22. Y. Kong, L. Si, and Y. Zhu Large-scale analysis of KIT aberrations in Chinese patients with melanoma Clin Cancer Res. 17 7 2011 1684 1691
23. J. Lennartsson, T. Jelacic, D. Linnekin, and R. Shivakrupa Normal and oncogenic forms of the receptor tyrosine kinase kit Stem Cells. 23 1 2005 16 43
24. K. Thommes, J. Lennartsson, M. Carlberg, and L. Ronnstrand Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor The Biochemical journal. 341 Pt 1 1999 211 216
25. U.B. Hofmann, C.S. Kauczok-Vetter, R. Houben, and J.C. Becker Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate Clin Cancer Res. 15 1 2009 324 329
26. K. Omholt, E. Grafstrom, L. Kanter-Lewensohn, J. Hansson, and B.K. Ragnarsson-Olding KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites Clin Cancer Res. 17 12 2011 3933 3942
27. C.A. Torres-Cabala, W.L. Wang, and J. Trent Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 22 11 2009 1446 1456
28. K.T. Montone, P. van Belle, R. Elenitsas, and D.E. Elder Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 10 9 1997 939 944
29. S.S. Shen, P.S. Zhang, O. Eton, and V.G. Prieto Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array Journal of cutaneous pathology. 30 9 2003 539 547
30. K.B. Kim, O. Eton, and D.W. Davis Phase II trial of imatinib mesylate in patients with metastatic melanoma Br J Cancer. 99 5 2008 734 740
31. D. Handolias, A.L. Hamilton, and R. Salemi Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT Br J Cancer. 102 8 2010 1219 1223
32. J. Guo, L. Si, and Y. Kong Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification J Clin Oncol. 29 21 2011 2904 2909
33. Kluger HM, Dudek A, McCann C, Rink L, Ritacco J, Adrada C, et al. A phase II trial of dasatinib in advanced melanoma. J Clin Oncol. 2009;27(suppl): abstract 9010.
34. S.E. Woodman, J.C. Trent, and K. Stemke-Hale Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates Mol Cancer Ther. 8 8 2009 2079 2085
35. Yamaguchi M, Harada K, Ando N, Kawamura T, Shibagaki N, Shimada S. Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb. Clin Exp Dermatol. 2010.
36. Zhu Y SL, Kong Y, Chi Z, Yuan X CC, Sheng X GJ, L S. Response to sunitinib in Chinese KIT -mutated metastatic mucosal melanoma. J Clin Oncol. 2009;27 ((suppl):abstract e20017).
37. C.M. Balch, J.E. Gershenwald, and S.J. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol. 27 36 2009 6199 6206
38. S.B. Edge, and C.C. Compton The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM Annals of surgical oncology. 17 6 2010 1471 1474
39. C. Tarn, E. Merkel, and A.A. Canutescu Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling Clin Cancer Res. 11 10 2005 3668 3677
40. R. Houben, C.S. Vetter-Kauczok, and S. Ortmann Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma J Invest Dermatol. 128 8 2008 2003 2012
41. S.N. Abysheva, A.G. Iyevleva, and N.V. Efimova KIT mutations in Russian patients with mucosal melanoma Melanoma research. 21 6 2011 555 559
42. B.C. Bastian, P.E. LeBoit, H. Hamm, E.B. Brocker, and D. Pinkel Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization Cancer Res. 58 10 1998 2170 2175
43. Schoenewolf NL, Urosevic-Maiwald M, Dummer R. Tumor heterogeneity of mucosal melanomas during treatment with imatinib. Br J Dermatol. 2011.